SCHEMBL2852148

SCHEMBL2852148

CCN(c1ccc(C(N)=O)cc1)C(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
PARP10 Q53GL7 4/20 0.44
HSD17B10 Q99714 1/20 0.43
ALDH1A1 P00352 6/20 0.43
CA2 P00918 2/20 0.40
PARP4 Q9UKK3 2/20 0.40
ESRRG P62508 1/20 0.40
CA1 P00915 1/20 0.40
PARP1 P09874 1/20 0.40
PARP2 Q9UGN5 1/20 0.40
MCL1 Q07820 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
IGLV6-57 P01721 1/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
PARP15 Q460N3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4867978 0.98 MAPT (0.48) MAPTL3MBTL1KMT2AMEN1PARP10
SCHEMBL18386561 0.84 KMT2A (0.50) MAPTL3MBTL1KMT2AMEN1ALDH1A1
SCHEMBL18387846 0.79 CA1 (0.56) MAPTL3MBTL1KMT2AMEN1ALDH1A1
SCHEMBL1128718 0.77 PARP10 (0.50) MAPTL3MBTL1KMT2APARP10HSD17B10
SCHEMBL1477967 0.77 MAPT (0.54) MAPTL3MBTL1KMT2AMEN1PARP10
SCHEMBL17774977 0.76 IGLV6-57 (0.41) MAPTL3MBTL1KMT2AMEN1HSD17B10
Hydrochloric Acid SCHEMBL3855035 0.76 MAPT (0.53) MAPTL3MBTL1KMT2AMEN1PARP10
SCHEMBL7790315 0.76 PARP10 (0.48) MAPTL3MBTL1KMT2APARP10HSD17B10
SCHEMBL13331926 0.76 ADRA2A (0.55) MAPTL3MBTL1KMT2APARP10HSD17B10
SCHEMBL1143293 0.75 ALDH1A1 (0.56) MAPTL3MBTL1KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP claimed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP disclosed
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 US disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES SCN3A, TRPV3, HCN3 MAPT 3590/4885L3MBTL1 4714/4885KMT2A 2659/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 MAPT 3590/4885L3MBTL1 4714/4885KMT2A 2659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.